The scientists and institutions, grans involved in the Ebola gain-of-function overlap with the people, research networks and arguments that became central to the covid-origin controversy and at the centre of those two networks are Gates and Fauci.
The strongest version of the overlap
1. Gates funded parts of the Ebola network.
Gates funding went to Corgenix for the ReEBOV Ebola diagnostic and to the Broad Institute for Ebola genomic sequencing. The Foundation's grant database is the primary place to establish the recipients and stated purposes.
So:
Gates → Corgenix/Broad → Ebola research
2. Those projects intersected with the Garry/KGH/VHFC network
The Ebola work at Kenema wasn't an isolated diagnostic project. KGH had an established viral-hemorrhagic-fever research program, and Garry's group worked with KGH and the wider VHFC. Garry subsequently described having worked with KGH for nearly two decades.
So you have:
Gates-funded Ebola projects ↔ Garry/VHFC ↔ KGH. The same KGH research infrastructure and cohorts subsequently entered coronavirus research
This is probably the most interesting direct overlap.
The pre-COVID Sierra Leone study explicitly says that researchers used blood samples collected before the COVID pandemic from Lassa fever and Ebola survivors and their contacts. It was conducted through the KGH/VHFC research setting.
And the author list includes Robert Garry and Kristian Andersen. Andersen's publication record identifies the study as a 2021 paper on cross-reactive SARS-CoV-2/MERS-CoV antibodies in pre-COVID Sierra Leone blood samples.
There is an actual biological/research continuity:
Ebola/Lassa survivor cohorts → stored pre-pandemic specimens → SARS-CoV-2 serological research.
Garry and Andersen then move directly into the COVID-origin debate
Garry's congressional testimony provides a particularly clear bridge. He says that after the first SARS-CoV-2 sequence was released, he participated with other scientists in the molecular/phylogenetic analysis that became The Proximal Origin of SARS-CoV-2. He explicitly places that work in the context of his nearly 20 years of work with KGH.
The chain is approximately:
Gates-funded Ebola research
↓
KGH / VHFC
↓
Garry + Andersen + associated institutions
↓
Ebola/Lassa survivor cohorts and biological samples
↓
pre-COVID SARS-CoV-2 research in Sierra Leone
↓
Garry + Andersen
↓
Proximal Origin
A. Funding overlap — established
Gates funded significant Ebola research involving institutions and researchers in this network.
B. Scientific/personnel/sample overlap — established
KGH/VHFC's Ebola/Lassa infrastructure, cohorts and researchers subsequently participated in coronavirus research.
C Gates funded significant covid research through EcoHealth.
The same institutional and scientific ecosystem that received Gates support during the Ebola outbreak subsequently used Ebola/Lassa survivor material and the established KGH/VHFC research infrastructure for pre-pandemic coronavirus research, while key researchers from that ecosystem—particularly Garry and Andersen—went on to participate in the SARS-CoV-2 origin analysis that produced Proximal Origin.
The Covid track
Coronavirus research—particularly research on SARS, MERS, and bat coronaviruses—was already active in 2014.
What was happening in 2014?
Fauci s pardon extends back to 2014.
The original NIH award was to EcoHealth Alliance, which subcontracted part of the work to WIV. GAO later identified a WIV NIH subaward of about $598,000 over the relevant five-year period.
There was also USAID's PREDICT program, which had supported coronavirus surveillance involving WIV/EcoHealth before and during this period.
What was actually being experimented on?
This is where the story becomes important.
The researchers were looking for SARS-like coronaviruses in bats, particularly viruses related to the virus that caused the 2003 SARS outbreak.
A major earlier discovery was published in 2013 by Shi Zhengli, Xing-Yi Ge, Peter Daszak and colleagues: they identified a bat coronavirus called WIV1 that could use the human SARS coronavirus receptor ACE2.
That work established that some naturally occurring bat coronaviruses possessed characteristics that potentially allowed them to infect human cells.
The 2014 program expanded this kind of investigation.
2015 — the particularly controversial experiment
This is probably the experiment you've heard about.
In 2015, a team involving:
Ralph Baric — University of North Carolina
Vineet Menachery and other UNC researchers
Zhengli Shi
Xing-Yi Ge — WIV
So it is accurate to say that U.S. federal money supported research involving WIV, but it is misleading to describe it as NIH directly giving a multi-million-dollar grant to the Wuhan laboratory.
published a paper in Nature Medicine called:
“A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.”
They took the spike protein from a bat coronavirus called SHC014 and put it onto a mouse-adapted SARS coronavirus backbone.
That created a chimeric virus.
They then tested it for characteristics including:
ability to use human ACE2;
replication in human airway cells;
replication in mice; and
susceptibility to existing SARS antibodies/vaccine approaches.
They also generated an infectious version of SHC014 itself using reverse genetics.
This was a genuine gain-of-function-type experiment, although terminology matters: scientists and policymakers have disagreed about exactly how this work should be classified under different definitions of “gain of function.”
The paper itself says the experiments involving the full-length and chimeric SHC014 viruses were initiated before the U.S. October 2014 funding pause and were subsequently reviewed and approved for continuation.
.
Funding
The 2015 paper acknowledges:
NIH/NIAID
NIH/National Institute on Aging
USAID PREDICT through EcoHealth Alliance
Chinese National Natural Science Foundation
among its sources of support.
Why October 2014 matters
Claim Evidence
Coronavirus research existed at WIV before COVID Yes
WIV/EcoHealth studied bat SARS-related coronaviruses Yes
U.S. government money supported some of this research Yes
NIH money reached WIV indirectly through EcoHealth Yes
Researchers performed experiments altering SARS-related coronavirus genomes Yes
A 2015 experiment created a SARS-like chimeric virus Yes
Some experiments tested infection of human airway cells and mice Yes
There is an overlap between the Kenema, Ebola and the Wuhan coronavirus network
Kenema/VHFC
NIH/NIAID → Tulane/VHFC → KGH
Gates → various research/response projects
DTRA → USAMRIID/Metabiota-related work
CDC → outbreak diagnostics
Broad/Harvard/Scripps/UTMB → scientific collaboration
Wuhan/EcoHealth
NIH/NIAID → EcoHealth Alliance → WIV
USAID/PREDICT → EcoHealth and collaborators
Chinese government funding → Chinese research institutions
WIV ↔ UNC/Baric and other international collaborators
Robert Garry and Kristian Anderson and Ian Lipkin were 3 of the five authors The Proximal Origin of SARS-CoV-2 who were also involved in the Kenema ebola genomic research.
The Gates Foundation funds research in several areas that are legitimately considered dual-use from a biosecurity perspective, particularly pathogen genomics, sequencing, diagnostics, epidemiology, and One Health surveillance.
Examples from its current public grant database:
- Pathogen genomic sequencing: In March 2026, the Foundation committed $25,000 for an economic study concerning procurement and delivery of pathogen genomic sequencing across African public-health programs.
- Genomic analysis: In June 2026, it committed $749,667 to the Broad Institute to develop pathogen-genomic data-analysis pipelines for malaria and other pathogens of public-health importance in Africa.
- One Health / animal-human-environment surveillance: In 2026, it committed $508,992 to Temasek Life Sciences Laboratory for a network integrating human, animal, and environmental data to predict, detect, and mitigate emerging infectious-disease threats in Asia-Pacific.
- Diagnostics: It has funded multiple low-cost molecular and point-of-care diagnostic projects, including a $846,097 grant to DCN Diagnostics and $2.72 million to Rapidemic for molecular diagnosis of infectious diseases.
- Sequencing for surveillance: It also funded the University of Birmingham to develop sequencing directly from cholera stool/wastewater samples to study transmission.
- Animal/infectious-disease surveillance: The Foundation gave the International Livestock Research Institute $1.45 million in 2026 to use advanced analytical tools for early detection and monitoring of infectious diseases.
The Foundation itself explicitly describes genomic sequencing, wastewater/environmental surveillance, and data modeling as tools for improving outbreak detection and public-health decision-making.
The same capabilities can have different applications:
| Capability | Public-health purpose | Why it can be dual-use |
|---|---|---|
| Pathogen sequencing | Track outbreaks and variants | Generates detailed pathogen genetic information |
| Genomic analysis | Determine transmission/evolution | Some information can have security implications |
| Animal-reservoir surveillance | Identify spillover risks | Maps pathogens and their natural hosts |
| Diagnostics | Detect infections quickly | Improves ability to recognize particular biological agents |
| Environmental surveillance | Detect pathogens before clinical outbreaks | Provides information about pathogen presence/distribution |
The Gates Foundation funding of dual use ebola and coivid research
| Capability | Ebola | COVID-19 | Dual-use concern |
|---|---|---|---|
| Genomic sequencing | Yes | Yes | Pathogen genetic information |
| Genomic surveillance | Yes | Yes | Tracking evolution/transmission |
| Animal-source surveillance | Less prominent in these grants | Yes | Human–animal pathogen interface |
| Diagnostics | Yes | Extensive | Detection capability |
| Epidemiological surveillance | Yes | Extensive | Mapping transmission |
| Vaccine/therapeutic R&D | Yes | Yes | Countermeasure development |